King Defense Against Generic ACE Inhibitors May Include Increased Spending
King will consider increasing marketing spend behind Altace (ramipril) in the second half of the year to strengthen the drug's position against generics of other angiotension converting enzyme inhibitors, CEO Brian Markison said during an Aug. 9 earnings call
You may also be interested in...
Data on antihypertensives that have shown cardiovascular endpoint benefits in well-controlled trials should be included in labeling, FDA and the Cardiovascular & Renal Drugs Advisory Committee agreed at a June 15 meeting
New indications for the ACE inhibitor Altace top the list of pipeline projects being developed by King to fuel future growth, the company said during an investor presentation April 12
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011